Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT01019772 Completed - Clinical trials for Infectious Disease by Haemophilus Influenzae Type b

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate and compare the immunogenicity and safety of LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of Hiberix™ at vaccination in healthy infants at their 2, 4, and 6 months of age.

NCT ID: NCT01019447 Completed - Clinical trials for Surgical Site Infection

The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection

Start date: November 2009
Phase: Phase 4
Study type: Interventional

To compare conventional polyglactin 910 sutures with triclosan-coated polyglactin 910 antimicrobial sutures for the reduction of surgical site infections and any associated health and economic benefits.

NCT ID: NCT01019395 Completed - Clinical trials for Gram Positive Bacterial Infection

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Start date: January 5, 2010
Phase: Phase 1
Study type: Interventional

This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 3 months to 24 months who have proven or suspected infections that are caused by a specific group of bacteria (called Gram-positive bacteria)or perioperative subjects that are receiving prophylactic antibiotics .

NCT ID: NCT01018641 Completed - Clinical trials for Bacterial Infections

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Start date: January 2010
Phase: Phase 1
Study type: Interventional

This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to assess how safe and well tolerated SA3Ag is, but will also describe the immune response over 12 months elicited by SA3Ag. Additionally, this study will assess the effect of SA3Ag vaccine on the number of Staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.

NCT ID: NCT01018095 Completed - HIV Infections Clinical Trials

Trichomonas Vaginalis Recurrence Among HIV+ Women

Start date: May 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

NCT ID: NCT01015014 Completed - Clinical trials for Gram-negative Bacterial Infection

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Start date: November 5, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.

NCT ID: NCT01008020 Completed - Influenza Infection Clinical Trials

Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection

Start date: November 2009
Phase: N/A
Study type: Interventional

The Purpose of this study is to evaluate the effects of 5 months catechin consumption on the prevention of influenza infection.

NCT ID: NCT01007487 Completed - Clinical trials for Surgical Site Infection

Plastic Wound Retractors and Bacterial Translocation in Abdominal Surgery

Start date: January 2008
Phase: N/A
Study type: Observational

Hypothesis: Plastic wound retractors reduce passage of bacteria from the abdomen to the surgical incision site in abdominal surgery Currently, plastic wound retractors are used in abdominal surgery to facilitate access to the abdominal cavity. This study aims to establish whether they also prevent bacteria crossing from the abdominal cavity to the surgical incision site. Patients undergoing abdominal surgery in which a plastic wound retractor (Alexis®)is used are eligible for inclusion in the study. Swabs are taken from the inside and the outside of the plastic wound retractor prior to removing the retractor from the abdomen. The bacterial flora from swabs taken inside and outside the plastic wound protector are then compared to see if there is any difference between inside and outside the retractor. Bacteria are classified as 'enteric'(i.e. from the gastrointestinal tract) or 'skin' bacteria, depending on their usual location. The study aims to establish whether a plastic wound retractor (Alexis®) reduces translocation of enteric bacteria to the surgical incision site.

NCT ID: NCT01006629 Completed - Clinical trials for Congenital Heart Disease

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Start date: November 2009
Phase: Phase 2/Phase 3
Study type: Interventional

100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial virus (RSV) infection in order to study the safety and efficacy of the drug in Russian subjects.

NCT ID: NCT01003587 Active, not recruiting - Clinical trials for Cardiovascular Disease

Promoting Evidence-Based Decision-Making in India: District Evaluation Study on Health

DESH
Start date: July 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the impact of disseminating information on comparative performance, along with actionable messages on how to improve health outcomes, to district-level decision-makers in India using a randomized, controlled design. This information should improve prioritization of health services by district health officers, budget allocation for health, and implementation of priority health services at the district level.